sunitinib,pembrolizumab,Lenvatinib
pfizer,merck,teva,Eisai pharmaceutical
['sunitinib', 'pembro']
lenalidomide plus pembrolizumab decreased the risk of disease progression or death on second-line therapy by 50% compared to sunitinib in the clear clinical trial. #kicsm #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.